{"organizations": [], "uuid": "6e5bcbfe8f79e313b43c9e0f3eba9464927a707d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-calithera-biosciences-says-plans-t/brief-calithera-biosciences-says-plans-to-initiate-a-global-randomized-phase-2-trial-of-cb-839-in-combination-with-cabozantinib-in-q2-of-2018-idUSFWN1PV1EK", "country": "US", "domain_rank": 408, "title": "BRIEF-Calithera Biosciences Says Plans To Initiate A Global, Randomized Phase 2 Trial Of CB-839 In Combination With Cabozantinib In Q2 Of 2018", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-06T00:17:00.000+02:00", "replies_count": 0, "uuid": "6e5bcbfe8f79e313b43c9e0f3eba9464927a707d"}, "author": "", "url": "https://www.reuters.com/article/brief-calithera-biosciences-says-plans-t/brief-calithera-biosciences-says-plans-to-initiate-a-global-randomized-phase-2-trial-of-cb-839-in-combination-with-cabozantinib-in-q2-of-2018-idUSFWN1PV1EK", "ord_in_thread": 0, "title": "BRIEF-Calithera Biosciences Says Plans To Initiate A Global, Randomized Phase 2 Trial Of CB-839 In Combination With Cabozantinib In Q2 Of 2018", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "calithera biosciences inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "calithera biosciences inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "#Market News   in 4 minutes BRIEF-Calithera Biosciences Says Plans To Initiate A Global, Randomized Phase 2 Trial Of CB-839 In Combination With Cabozantinib In Q2 Of 2018 Reuters Staff 1 Min Read \nFeb 5 (Reuters) - Calithera Biosciences Inc: \n* CALITHERA BIOSCIENCES INC - PLAN TO INITIATE A GLOBAL, RANDOMIZED PHASE 2 TRIAL OF CB-839 IN COMBINATION WITH CABOZANTINIB IN Q2 OF 2018 Source text for Eikon:  ", "external_links": [], "published": "2018-02-06T00:17:00.000+02:00", "crawled": "2018-02-06T00:32:26.000+02:00", "highlightTitle": ""}